Lapatinib

Type: Keyphrase
Name: Lapatinib
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1

by Guangyuan Li, Xiaoqi Wang, Hanina Hibshoosh, Cheng Jin, Balazs HalmosWe set out to study the key effectors of resistance and sensitivity to ErbB2 tyrosine kinase inhibitors, such as lapatinib in ErbB2-positive breast and lung cancers. A cell-based ... [Published Plosone.org - Sep 19 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

HER2 in Trastuzumab/Emtansine vs Trastuzumab/Docetaxel

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl ... [Published General Medicine eJournal - Sep 19 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Epizyme announces management changes

Epizyme, Inc., a clinical stage biopharmaceutical company, has appointed Peter Ho as chief development officer and Michael Shih as vice president of business development. "We are very pleased to welcome Peter and Michael to Epizyme," said Robert Gould, ... [Published Individual.com - Sep 17 2014]
First reported Sep 09 2014 - Updated Sep 10 2014 - 1 reports

Hurvitz Discusses PIK3CA Mutations, pCR, CDK4/6 Inhibitors, Immunotherapies in Breast Cancer

Sara Hurvitz, MDAt the 13th Annual Congress on the Future of Breast Cancer, Sara Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center (JCCC), discussed “ PIK3CA Mutations in HER2+ Breast Cancer.” In an interview with Oncology & Biotech News (OBTN) , ... [Published OncLive - Sep 09 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells

by Li Yin, Xin-Tian Zhang, Xiu-Wu Bian, Yu-Ming Guo, Zhao-Yi WangTamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, most breast tumors develop tamoxifen resistance and are eventually refractory to tamoxifen ... [Published Plosone.org - Sep 09 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 2 reports

Studies from University of Nebraska Provide New Data on Breast Cancer (Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant...

Studies from University of Nebraska Provide New Data on Breast Cancer (Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer) By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on Oncology is ... [Published TVNewsCheck - Sep 05 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Study Data from GlaxoSmithKline Update Knowledge of Oncology Research (Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk...

Study Data from GlaxoSmithKline Update Knowledge of Oncology Research (Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury)By a News Reporter-Staff News Editor at Clinical Trials Week ... [Published 4 Traders - Sep 04 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

[Comment] Dual targeting of HER2 with lapatinib and trastuzumab

Drugs targeting HER2 are central to the treatment of patients with HER2-positive breast cancer, and dual targeting of HER2 with two drugs has gained much attention since 2010. 1 Patients with metastatic HER2-positive breast cancer have better overall ... [Published Lancet Oncology - Sep 02 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib - Abstract

Lapatinib, a dual tyrosine kinase inhibitor of ErbB1 and ErbB2, shows a clinical benefit in a subset of patients with advanced urothelial bladder cancer (UBC).We hypothesized that the corresponding gene, ERBB2, is affected by mutations in a subset of ... [Published UroToday - Aug 28 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

NHI will cover new cancer drug

A new orally administered targeted therapy for metastatic breast cancer that has spread to the brain is to be covered by the National Health Insurance (NHI) program, in an effort to substantially reduce patients’ medical costs, the NHI Administration ... [Published Taipei Times Online - Aug 26 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

Comment Dual targeting of HER2 with lapatinib and trastuzumab

Relevant TopicsBreast CancerLatest News Clinical Trials Research Drugs Reports CorporateTrack and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical ... [Published BioPortfolio - Aug 16 2014]
First reported Jun 02 2014 - Updated Jun 03 2014 - 3 reports

ASCO 2014 GSK's 'profound' ALTTO failure of breast cancer combo

| SCRIPThe Phase III study of a combination of two anti-HER2 agents, GlaxoSmithKline's lapatinib (Tykerb/Tyverb) and Roche's trastuzumab (Herceptin), did not meet the primary endpoint of improved disease-free survival (DFS) compared with single-agent ... [Published BioPortfolio - Jun 02 2014]

Quotes

...proprietary product platform and intellectual property position, first_in class clinical programs and strong balance sheet," said Mr Shih. "I'm excited to be joining the Company and look forward to contributing to its future success through strategic partnerships."
According to the news editors, the research concluded: "Thus these, and other ADCs in development, promise to achieve the long sought goal of ADC technology, that is, of having compounds with high anti-tumour activity at doses where adverse effects are generally mild."
The email stated: "GSK has been engaging in multiple corrupt and illegal practices in conducting its pharmaceutical business in Syria."
According to the news reporters, the research concluded: "We have developed PEG-PBC micelle formulations for the delivery of doxorubicin and lapatinib. The combination therapy of doxorubicin plus lapatinib has a great potential for treating MDR breast cancer."

More Content

All (43) | News (37) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Modulation of ErbB2 Blockade in ErbB2-Positive ... [Published Plosone.org - Sep 19 2014]
HER2 in Trastuzumab/Emtansine vs Trastuzumab/Do... [Published General Medicine eJournal - Sep 19 2014]
Epizyme announces management changes [Published Individual.com - Sep 17 2014]
Investigators at ImmunoGen Report New Data on C... [Published 4 Traders - Sep 11 2014]
Molecular study confirms 4 different HER2 brea... [Published Ecancer Medicalscience - Sep 10 2014]
August’s top stories: Major buys by Roche and M... [Published Pharmaceutical Technology - Sep 10 2014]
Disruption of the ER-α36-EGFR/HER2 Positive Reg... [Published Plosone.org - Sep 09 2014]
Hurvitz Discusses PIK3CA Mutations, pCR, CDK4/6... [Published OncLive - Sep 09 2014]
Studies from University of Nebraska Provide New... [Published TVNewsCheck - Sep 05 2014]
Studies from University of Nebraska Provide New... [Published HispanicBusiness.com - Sep 05 2014]
Merrimack Pharmaceuticals : "Methods for Preven... [Published 4 Traders - Sep 04 2014]
Study Data from GlaxoSmithKline Update Knowledg... [Published 4 Traders - Sep 04 2014]
Subtype, pCR Predict Locoregional Recurrence Fo... [Published OncLive - Sep 02 2014]
[Comment] Dual targeting of HER2 with lapatinib... [Published Lancet Oncology - Sep 02 2014]
MacroGenics: A Late Stage Pipeline Review [Published Seeking Alpha - Aug 30 2014]
Impact of ERBB2 mutations on in vitro sensitivi... [Published UroToday - Aug 28 2014]
Researchers from Uppsala University Describe Fi... [Published HispanicBusiness.com - Aug 28 2014]
NHI will cover new cancer drug [Published Taipei Times Online - Aug 26 2014]
How We Treat Patients with Gastric Cancer [Published Oncology Times - Aug 22 2014]
Top 3 lessons learned from ICE/ENDO 2014 [Published Orthopedics Today - Aug 19 2014]
Comment Dual targeting of HER2 with lapatinib a... [Published BioPortfolio - Aug 16 2014]
Takeaways from the ASCO Annual Meeting from Gor... [Published Oncology Times - Aug 14 2014]
NICE rejects Roche’s new breast cancer drug ove... [Published Pharmaceutical Technology - Aug 11 2014]
Neratinib Comes Through For Puma [Published In the Pipeline - Jul 23 2014]
Doomed future for Tykerb in breast cancer arena... [Published BioPortfolio - Jun 16 2014]
GSK's Tykerb "Little More" to Offer [Published Pharmaceutical Executive - Jun 13 2014]
Tykerb and Herceptin Combination Therapy Fails ... [Published BioPortfolio - Jun 10 2014]
ASCO 2014 GSK's 'profound' ALTTO failure of bre... [Published BioPortfolio - Jun 02 2014]
GSK's Phase III trial of breast cancer combinat... [Published BioPortfolio - Jun 02 2014]
GSK's Phase III trial of breast cancer combinat... [Published PBR - News - Jun 02 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Neratinib Comes Through For Puma [Published In the Pipeline - Jul 23 2014]
Yet another entry in the "Why do people keep investing in biopharma?" files. Take a look at the case of Puma Biotechnology. Their stock was as high as $140/share earlier in the year, and it gradually deflated to the high 50s/low 60s as time went on. ...
GSK's Phase III trial of breast cancer combinat... [Published PBR - News - Jun 02 2014]
UK-based drug maker GlaxoSmithKline (GSK) has reported results from its Phase III trial of two anti-HER2 agents, lapatinib (Tykerb/Tyverb) and trastuzumab, as an adjuvant treatment for patients with HER2 positive primary breast cancer. ...
Cost Control in the UK [Published Balloon Juice - Apr 23 2014]
Via the Guardian: A Herceptin-style drug that can offer some women with advanced breast cancer nearly six months of extra life has been turned down for use in the NHS because of its high cost. In draft guidance now open to consultation, the ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Apr 01 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.